Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

September 17, 2019

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

July 9, 2019

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers

January 3, 2019

REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019

November 13, 2018

REVOLUTION Medicines Announces Presentations at Scientific Meetings in Third and Fourth Quarters of 2018

October 16, 2018

REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

October 9, 2018

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

July 18, 2018

Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

April 24, 2018

REVOLUTION Medicines Raises $56 Million Series B Financing

October 5, 2017

REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors

September 14, 2017

Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 21 - 30 of 40

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations